Literature DB >> 24266954

Functional restoration of diaphragmatic paralysis: an evaluation of phrenic nerve reconstruction.

Matthew R Kaufman1, Andrew I Elkwood2, Alan R Colicchio3, John CeCe4, Reza Jarrahy5, Lourens J Willekes6, Michael I Rose2, David Brown7.   

Abstract

BACKGROUND: Unilateral diaphragmatic paralysis causes respiratory deficits and can occur after iatrogenic or traumatic phrenic nerve injury in the neck or chest. Patients are evaluated using spirometry and imaging studies; however, phrenic nerve conduction studies and electromyography are not widely available or considered; thus, the degree of dysfunction is often unknown. Treatment has been limited to diaphragmatic plication. Phrenic nerve operations to restore diaphragmatic function may broaden therapeutic options.
METHODS: An interventional study of 92 patients with symptomatic diaphragmatic paralysis assigned 68 (based on their clinical condition) to phrenic nerve surgical intervention (PS), 24 to nonsurgical (NS) care, and evaluated a third group of 68 patients (derived from literature review) treated with diaphragmatic plication (DP). Variables for assessment included spirometry, the Short-Form 36-Item survey, electrodiagnostics, and complications.
RESULTS: In the PS group, there was an average 13% improvement in forced expiratory volume in 1 second (p < 0.0001) and 14% improvement in forced vital capacity (p < 0.0001), and there was corresponding 17% (p < 0.0001) and 16% (p < 0.0001) improvement in the DP cohort. In the PS and DP groups, the average postoperative values were 71% for forced expiratory volume in 1 second and 73% for forced vital capacity. The PS group demonstrated an average 28% (p < 0.01) improvement in Short-Form 36-Item survey reporting. Electrodiagnostic testing in the PS group revealed a mean 69% (p < 0.05) improvement in conduction latency and a 37% (p < 0.0001) increase in motor amplitude. In the NS group, there was no significant change in Short-Form 36-Item survey or spirometry values.
CONCLUSIONS: Phrenic nerve operations for functional restoration of the paralyzed diaphragm should be part of the standard treatment algorithm in the management of symptomatic patients with this condition. Assessment of neuromuscular dysfunction can aid in determining the most effective therapy.
Copyright © 2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  6

Mesh:

Year:  2013        PMID: 24266954     DOI: 10.1016/j.athoracsur.2013.09.052

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Phrenic nerve stimulation during neck dissection for advanced thyroid cancer involving level IV: is it worth doing it?

Authors:  Carlos S Duque; Juan P Dueñas; Marcela Marulanda; Diana Pérez; Andres Londoňo; Soham Roy; Mai Al Khadem
Journal:  Updates Surg       Date:  2017-02-13

2.  Treatment for bilateral diaphragmatic dysfunction using phrenic nerve reconstruction and diaphragm pacemakers.

Authors:  Matthew R Kaufman; Thomas Bauer; Raymond P Onders; David P Brown; Eric I Chang; Kristie Rossi; Andrew I Elkwood; Ethan Paulin; Reza Jarrahy
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-05-10

3.  Klippel-feil syndrome and unilateral diaphragmatic paralysis.

Authors:  John Cece; Farid Aboharb; Kameron S Rezzadeh; David Brown; Reza Jarrahy; Matthew R Kaufman
Journal:  Eplasty       Date:  2015-02-10

4.  Thoracoscopic one-stage lobectomy and diaphragmatic plication for T3 lung cancer.

Authors:  Yuki Takahashi; Masahiro Miyajima; Taijiro Mishina; Ryunosuke Maki; Makoto Tada; Kodai Tsuruta; Atsushi Watanabe
Journal:  J Cardiothorac Surg       Date:  2018-07-09       Impact factor: 1.637

5.  Importance of muldisciplinary management of giant mediastinal sarcoma: A case report with phrenic nerve reconstruction.

Authors:  Luca Frasca; Filippo Longo; Giovanni Tacchi; Francesco Stilo; Anna Zito; Beniamino Brunetti; Massimiliano Depalma; Pierfilippo Crucitti
Journal:  Thorac Cancer       Date:  2020-04-23       Impact factor: 3.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.